Compass Wealth Management LLC Reduces Stake in Bristol-Myers Squibb (NYSE:BMY)

Compass Wealth Management LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 62.3% during the third quarter, Holdings Channel reports. The firm owned 2,198 shares of the biopharmaceutical company’s stock after selling 3,632 shares during the quarter. Compass Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $114,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BMY. ESL Trust Services LLC purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $27,000. LGT Financial Advisors LLC raised its position in Bristol-Myers Squibb by 42.7% during the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 227 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Bristol-Myers Squibb in the third quarter valued at about $34,000. MFA Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $39,000. Finally, Beach Investment Counsel Inc. PA purchased a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth approximately $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research note on Thursday. They issued a “market perform” rating and a $56.00 target price on the stock. UBS Group upped their price objective on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. TD Cowen lifted their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Finally, Barclays raised their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research note on Monday, October 7th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $53.20.

Bristol-Myers Squibb Stock Down 0.4 %

BMY stock opened at $53.18 on Friday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $57.59. The company has a 50 day moving average price of $50.23 and a two-hundred day moving average price of $46.41. The stock has a market capitalization of $107.80 billion, a P/E ratio of -17.15, a PEG ratio of 13.75 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. During the same period in the previous year, the company earned $1.75 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.51%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.